News – Page 414 – Endpoints News

Omnibus spending bill features funding to bolster the supply chain and site inspections

3 years ago

What's next at Endpoints: a bigger, more ambitious newsroom

3 years ago

Trends for 2023: What's coming next in pharma marketing and drug commercialization?

3 years ago

MarketingRx roundup: Roche, Pfizer team up for Covid awareness; Merck joins $50M Africa-focused coalition

3 years ago

Blaming placebo response for 'uninterpretable' PhIII results, ContraFect calls for new antibiotic study

3 years ago

Verona says second PhIII for COPD drug hits the mark, plans 2023 NDA filing

3 years ago

Catalyst Pharmaceuticals to acquire commercial rights to an Eisai seizure medication for $160M

3 years ago

Magenta's blood cancer ADC faces two dose-limiting toxicities, triggering cohort stoppage

3 years ago

In yet another delay for the F-star buyout, CFIUS extends review of 'national security risks'

3 years ago

A NASH biotech plans $75M offering, Arrowhead nabs Amgen payment and Astria raises $115M

3 years ago

Gilead's Kite nabs Carl June spinout Tmunity after neurotox kills patients, forcing reorg — and a rethink

3 years ago

California hearing-loss biotech fires all employees and outlines plan to liquidate

3 years ago

Accelerated approval reforms make the cut in year-end government spending bill

3 years ago

Entrada hit with clinical hold on Duchenne drug

3 years ago

Gilead and Arcus want you to believe again in TIGIT. But mixed ARC-7 data are rolling out to a tough crowd

3 years ago

Boehringer Ingelheim deepens its collaboration with Click Therapeutics in a deal worth $460M

3 years ago

Novartis to cut 280+ jobs in New Jersey

3 years ago

EC approves first allogeneic T cell therapy for rare post-transplant complication

3 years ago

FDA reports shortages for two of Eli Lilly's diabetes drugs will extend into next year

3 years ago

AbbVie adds depression indication to Vraylar's label months after Gonzalez touts $4B+ peak sales potential

3 years ago

Genentech and Biogen pen royalty deal for blood cancer drug with big potential

3 years ago

Zymeworks shows positive — yet early — pivotal data in bile duct cancers, plans accelerated approval run

3 years ago

Wall Street still sees an upside for rare disease drug development as FDA looks to fill knowledge gaps

3 years ago

Taysha CEO steps down after patent fights with patient families, job cuts

3 years ago

First page Previous page 411 412 413414415 416 417 Next page Last page